Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer

Colorectal cancer (CRC) is among the most common malignancies in China, and approximately half of all patients develop liver metastases. For patients with resectable or potentially resectable liver-only metastases, R0 metastasectomy followed by perioperative chemotherapy is the current standard. However, recurrence rates remain high, especially in patients with high recurrence risk. This phase III study investigates whether an additional 6 months of adjuvant extended therapy with the oral tyrosine kinase inhibitor fruquintinib combined with capecitabine improves disease-free survival compared with guideline-recommended observation, in patients who have completed R0 resection and at least 3 months of perioperative chemotherapy for liver-only metastatic CRC.